PE20210108A1 - Composicion que comprende probioticos y polipeptido que tiene afinidad de union para ige y uso de la misma - Google Patents
Composicion que comprende probioticos y polipeptido que tiene afinidad de union para ige y uso de la mismaInfo
- Publication number
- PE20210108A1 PE20210108A1 PE2020000943A PE2020000943A PE20210108A1 PE 20210108 A1 PE20210108 A1 PE 20210108A1 PE 2020000943 A PE2020000943 A PE 2020000943A PE 2020000943 A PE2020000943 A PE 2020000943A PE 20210108 A1 PE20210108 A1 PE 20210108A1
- Authority
- PE
- Peru
- Prior art keywords
- ige
- composition
- polypeptide
- probiotics
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invencion se refiere a una composicion que contiene, como ingredientes activos, probioticos y un polipeptido con capacidad de union a IgE. En particular, se identifico un efecto sinergico de disminucion notable de la alergia alimentaria en el momento de la administracion combinada de probioticos y una proteina recombinante que contiene un dominio extracelular de una subunidad alfa de un receptor Fc de IgE de conformidad con la presente invencion. Por lo tanto, se espera que la composicion de la presente invencion sea altamente aplicable industrialmente debido a que puede presentar un efecto terapeutico notable sobre una enfermedad alergica mediada por IgE en comparacion con las composiciones farmaceuticas convencionales
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20180004421 | 2018-01-12 | ||
PCT/KR2019/000524 WO2019139434A1 (ko) | 2018-01-12 | 2019-01-14 | 프로바이오틱스 및 ige에 결합능이 있는 폴리펩티드를 포함하는 조성물 및 이의 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20210108A1 true PE20210108A1 (es) | 2021-01-19 |
Family
ID=67218660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020000943A PE20210108A1 (es) | 2018-01-12 | 2019-01-14 | Composicion que comprende probioticos y polipeptido que tiene afinidad de union para ige y uso de la misma |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220347236A1 (es) |
EP (1) | EP3738599B1 (es) |
JP (1) | JP7041272B2 (es) |
KR (1) | KR102038679B1 (es) |
CN (1) | CN111587118B (es) |
AU (1) | AU2019206205A1 (es) |
BR (1) | BR112020013818A2 (es) |
CA (1) | CA3086224A1 (es) |
CL (1) | CL2020001800A1 (es) |
ES (1) | ES2969110T3 (es) |
IL (1) | IL275593B (es) |
MX (1) | MX2020007032A (es) |
PE (1) | PE20210108A1 (es) |
PH (1) | PH12020551069A1 (es) |
SG (1) | SG11202005863TA (es) |
TW (1) | TWI737955B (es) |
WO (1) | WO2019139434A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102561135B1 (ko) * | 2019-07-08 | 2023-07-31 | (주)지아이이노베이션 | IgE Fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 시알산 함량이 높은 폴리펩티드 이량체 및 이를 포함하는 약학적 조성물 |
CN116348605A (zh) * | 2020-07-17 | 2023-06-27 | Gi 医诺微新 | 包含IgE Fc受体α亚基胞外结构域和抗IL-4R抗体的融合蛋白及其应用 |
KR20220011931A (ko) * | 2020-07-22 | 2022-02-03 | (주)지아이이노베이션 | IgE Fc 수용체를 포함하는 융합단백질 및 이를 포함하는 개 알레르기성 질환 치료 용도 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH092959A (ja) * | 1995-06-16 | 1997-01-07 | Yakult Honsha Co Ltd | IgE抗体産生抑制剤および抗アレルギー剤 |
JPH10309178A (ja) * | 1997-05-09 | 1998-11-24 | Wakamoto Pharmaceut Co Ltd | ビフィズス菌を有効成分とする抗アレルギー剤および醗酵食品 |
JP2000095697A (ja) | 1998-09-18 | 2000-04-04 | Advance Co Ltd | 抗アレルギー剤 |
AUPQ415899A0 (en) * | 1999-11-19 | 1999-12-16 | Vasse Research Institute Pty Ltd | Compositions for and methods of treatment of allergic diseases |
EP1239032A1 (en) * | 2001-03-02 | 2002-09-11 | Société des Produits Nestlé S.A. | Lactic acid bacteria as agents for treating and preventing allergy |
JP2009067679A (ja) | 2005-12-27 | 2009-04-02 | Univ Of Tokushima | 抗ヒスタミン作用を有する医薬 |
WO2008028068A2 (en) * | 2006-08-30 | 2008-03-06 | Genentech, Inc. | NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES |
US20100303777A1 (en) * | 2006-12-14 | 2010-12-02 | Actogenix N.V. | Delivery of binding molecules to induce immunomodulation |
AR065368A1 (es) | 2007-02-15 | 2009-06-03 | Astrazeneca Ab | Anticuerpos para moleculas de ige |
CN103641919B (zh) | 2007-05-30 | 2017-04-05 | 浦项工科大学校产学协力团 | 免疫球蛋白融合蛋白 |
EP2065048A1 (en) * | 2007-11-30 | 2009-06-03 | Institut Pasteur | Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation |
CN101939411A (zh) | 2008-02-06 | 2011-01-05 | 宝洁公司 | 用于提高呼吸病症免疫应答的组合物、方法和试剂盒 |
WO2010013143A2 (en) * | 2008-08-01 | 2010-02-04 | Institut Pasteur | Methods for inhibiting mast cell activation and treating mast cell-dependent inflammatory diseases and disorders using lactobacillus |
HUE042901T2 (hu) | 2008-09-17 | 2019-07-29 | Xencor Inc | Készítmények és eljárások IgE által közvetített rendellenességek kezelésére |
RU2642295C2 (ru) * | 2009-10-26 | 2018-01-24 | Дженентек, Инк. | АНАЛИЗЫ ОПРЕДЕЛЕНИЯ АНТИТЕЛ, СПЕЦИФИЧНЫХ К ТЕРАПЕВТИЧЕСКИМ АНТИТЕЛАМ ПРОТИВ IgE, И ИХ ПРИМЕНЕНИЕ ПРИ АНАФИЛАКСИИ |
KR20120135865A (ko) * | 2011-06-07 | 2012-12-17 | (주)네오팜 | FcεRI의 수용성 단편을 포함하는 복합체 및 이를 포함하는 IgE 매개 알레르기성 질환 치료용 조성물 |
WO2012169735A2 (ko) * | 2011-06-07 | 2012-12-13 | (주)네오팜 | FCεRI의 수용성 단편을 포함하는 복합체 및 이를 포함하는 IGE 매개 알레르기성 질환 치료용 조성물 |
CN103169733B (zh) * | 2011-12-26 | 2014-11-12 | 浙江贝因美科工贸股份有限公司 | 复合益生菌、其在治疗过敏性疾病中的应用及孕产妇防过敏益生菌冲剂 |
TWI691512B (zh) | 2015-02-20 | 2020-04-21 | 日商橘生藥品工業股份有限公司 | Fc融合高親和性IgE受體α鏈 |
JP2018515426A (ja) * | 2015-03-12 | 2018-06-14 | ザ ユニヴァーシティ オブ ブリティッシュ コロンビア | 細菌組成物およびその使用方法 |
KR101778734B1 (ko) | 2016-03-11 | 2017-09-18 | 대한민국(농촌진흥청장) | 비피도박테리움 롱검 kacc 91563으로부터 분리된 esbp 및 이를 이용한 항알레르기 조성물 |
US20210070833A1 (en) * | 2018-01-08 | 2021-03-11 | Gl INNOVATION, INC. | Extracellular domain of alpha subunit of ige fc receptor, pharmaceutical composition comprising same and method for producing same |
WO2019135666A1 (ko) * | 2018-01-08 | 2019-07-11 | 주식회사 프로젠 | Ige fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 약학적 조성물 |
-
2019
- 2019-01-14 CA CA3086224A patent/CA3086224A1/en active Pending
- 2019-01-14 EP EP19738433.2A patent/EP3738599B1/en active Active
- 2019-01-14 PE PE2020000943A patent/PE20210108A1/es unknown
- 2019-01-14 SG SG11202005863TA patent/SG11202005863TA/en unknown
- 2019-01-14 MX MX2020007032A patent/MX2020007032A/es unknown
- 2019-01-14 JP JP2020537681A patent/JP7041272B2/ja active Active
- 2019-01-14 BR BR112020013818-5A patent/BR112020013818A2/pt unknown
- 2019-01-14 KR KR1020190004610A patent/KR102038679B1/ko active IP Right Grant
- 2019-01-14 WO PCT/KR2019/000524 patent/WO2019139434A1/ko unknown
- 2019-01-14 AU AU2019206205A patent/AU2019206205A1/en active Pending
- 2019-01-14 TW TW108101372A patent/TWI737955B/zh active
- 2019-01-14 US US16/959,016 patent/US20220347236A1/en active Pending
- 2019-01-14 ES ES19738433T patent/ES2969110T3/es active Active
- 2019-01-14 CN CN201980008124.5A patent/CN111587118B/zh active Active
-
2020
- 2020-06-22 IL IL275593A patent/IL275593B/en unknown
- 2020-07-03 CL CL2020001800A patent/CL2020001800A1/es unknown
- 2020-07-10 PH PH12020551069A patent/PH12020551069A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3738599B1 (en) | 2023-12-27 |
EP3738599A1 (en) | 2020-11-18 |
US20220347236A1 (en) | 2022-11-03 |
CN111587118A (zh) | 2020-08-25 |
ES2969110T3 (es) | 2024-05-16 |
KR102038679B1 (ko) | 2019-10-30 |
TW201932129A (zh) | 2019-08-16 |
MX2020007032A (es) | 2020-12-03 |
CA3086224A1 (en) | 2019-07-18 |
JP2021510689A (ja) | 2021-04-30 |
BR112020013818A2 (pt) | 2020-12-01 |
CN111587118B (zh) | 2023-11-21 |
KR20190086396A (ko) | 2019-07-22 |
EP3738599C0 (en) | 2023-12-27 |
TWI737955B (zh) | 2021-09-01 |
RU2020122021A (ru) | 2022-02-14 |
AU2019206205A1 (en) | 2020-06-25 |
JP7041272B2 (ja) | 2022-03-23 |
SG11202005863TA (en) | 2020-07-29 |
IL275593B (en) | 2022-01-01 |
PH12020551069A1 (en) | 2021-09-06 |
EP3738599A4 (en) | 2021-10-27 |
WO2019139434A1 (ko) | 2019-07-18 |
IL275593A (en) | 2020-08-31 |
CL2020001800A1 (es) | 2020-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020001800A1 (es) | Composición que comprende probióticos y polipéptido que tiene afinidad de unión para ige y uso de la misma. | |
CL2020001762A1 (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464) | |
CL2017000201A1 (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
NI201700073A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
CO2019011021A2 (es) | Formulacion estable de anticuerpos | |
CO2017002166A2 (es) | Proteínas de fusión de interleucina 2 / receptor de interleucina-2 alfa | |
BR112018072915A2 (pt) | peptídeo cíclico isolado e composição farmacêutica | |
AR100945A1 (es) | Proteínas de fusión mic-1 y usos de las mismas | |
CL2017000999A1 (es) | Polipéptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos. | |
PE20151421A1 (es) | Formulacion liquida del conjugado de proteina que comprende la oxintomodulina y un fragmento de inmunoglobulina | |
BR112016014969A2 (pt) | polipeptídeo, formulação farmacêutica e uso de um polipeptídeo | |
MX2021010809A (es) | Citocina fusionada a fc heterodimerico, y composicion farmaceutica que comprende la misma. | |
CL2015001984A1 (es) | (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos. | |
BRPI0816784A8 (pt) | Fatores neuro-endócrinos para o tratamento de doenças degenerativas | |
BR112015024587A2 (pt) | variante de região fc | |
CR20120026A (es) | Construcciones novedosas de proteína del virus de papiloma humano (hpv) y su uso en la prevención de la enfermedad por el hpv | |
ECSP12011803A (es) | Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas | |
BR112018001761A2 (pt) | uso de variantes de peptídeo natriurético tipo c para tratar a displasia esquelética | |
PE20190110A1 (es) | Proteinas f de prefusion del vrs estabilizadas | |
PH12020551500A1 (en) | Viscosity reduction of highly concentrated protein formulations | |
SA521421715B1 (ar) | تركيبات سيماجلوتيد ثابتة واستخداماتها | |
CO2019006652A2 (es) | Amidas aromáticas de ácidos carboxílicos como antagonistas del receptor de bradiquinina b1 | |
PE20151866A1 (es) | Composiciones nutricionales que contienen un componente peptidico con propiedades estimulantes de adiponectina y usos del mismo | |
DOP2019000156A (es) | Fenitoina topica para uso en el tratamiento del dolor neuropático periférico | |
PE20151999A1 (es) | Composiciones nutricionales que contienen un componente peptidico y usos del mismo |